Secnidazole: a treatment for trichomoniasis in adolescents and adults

References

• Rowley J, Vander Hoorn S, Korenromp E, et al. Chlamydia, gonorrhoea, trichomoniasis and syphilis: global prevalence and incidence estimates, 2016. Bull World Health Organ. 2019;97(8):548–562.
   PubMed Web of Science ®Google Scholar
• Workowski KA, Bachmann LH, Chan PA, et al., Sexually transmitted infections treatment guidelines, 2021. MMWR Recomm Rep. 70(4): 1–187. 2021.
   PubMed Web of Science ®Google Scholar
• Flagg EW, Meites E, Phillips C, et al. Prevalence of trichomonas vaginalis among civilian, noninstitutionalized male and female population aged 14 to 59 years: United States, 2013 to 2016. Sex Transm Dis. 2019;46(10):e93–e96.
   PubMed Web of Science ®Google Scholar
• Daugherty M, Glynn K, Byler T. Prevalence of trichomonas vaginalis infection among US males, 2013-2016. Clin Infect Dis. 2019;68(3):460–465.
   PubMedGoogle Scholar
• Meites E. Trichomoniasis: the “neglected” sexually transmitted disease. Infect Dis Clin North Am. 2013;27(4):755–764.
   PubMedGoogle Scholar
• Sutton M, Sternberg M, Koumans EH, et al. The prevalence of trichomonas vaginalis infection among reproductive-age women in the United States, 2001-2004. Clin Infect Dis. 2007;45(10):1319–1326.
   PubMed Web of Science ®Google Scholar
• Seña AC, Goldstein LA, Ramirez G, et al. Bacterial vaginosis and its association with incident trichomonas vaginalis infections: a systematic review and meta-analysis. Sex Transm Dis. 2021 in press;48:e192–e201.
   PubMedGoogle Scholar
• Seña AC, Miller WC, Hobbs MM, et al. Trichomonas vaginalis infection in male sexual partners: implications for diagnosis, treatment, and prevention. Clin Infect Dis. 2007;44(1):13–22.
   PubMed Web of Science ®Google Scholar
• Committee on Practice Bulletins-Gynecology. Vaginitis in nonpregnant patients: ACOG practice bulletin, number 215. Obstet Gynecol. 2020;135(1):e1–e17.
   PubMedGoogle Scholar
• Moodley P, Wilkinson D, Connolly C, et al. Trichomonas vaginalis is associated with pelvic inflammatory disease in women infected with human immunodeficiency virus. Clin Infect Dis. 2002;34(4):519–522.
   PubMed Web of Science ®Google Scholar
• Yagur Y, Weitzner O, Tiosano LB, et al. Characteristics of pelvic inflammatory disease caused by sexually transmitted disease - an epidemiologic study. J Gynecol Obstet Hum Reprod. 2021;50:102176.
   PubMedGoogle Scholar
• Yang S, Zhao W, Wang H, et al. Trichomonas vaginalis infection-associated risk of cervical cancer: a meta-analysis. Eur J Obstet Gynecol Reprod Biol. 2018;228:166–173.
   PubMedGoogle Scholar
• Mielczarek E, Blaszkowska J. Trichomonas vaginalis: pathogenicity and potential role in human reproductive failure. Infection. 2016;44(4):447–458.
   PubMed Web of Science ®Google Scholar
• Silver BJ, Guy RJ, Kaldor JM, et al. Trichomonas vaginalis as a cause of perinatal morbidity: a systematic review and meta-analysis. Sex Transm Dis. 2014;41(6):369–376.
   PubMed Web of Science ®Google Scholar
• Van Gerwen OT, Craig-Kuhn MC, Jones AT, et al. Trichomoniasis and adverse birth outcomes: a systematic review and meta-analysis. Bjog. 2021;128(12):1907–1915.
   PubMedGoogle Scholar
• Sobel JD, Subramanian C, Foxman B, et al. Mixed vaginitis-more than coinfection and with therapeutic implications. Curr Infect Dis Rep. 2013;15(2):104–108.
   PubMed Web of Science ®Google Scholar
• Van Gerwen OT, Camino AF, Sharma J, et al. Epidemiology, natural history, diagnosis, and treatment of trichomonas vaginalis in men. Clin Infect Dis. 2021;73:1119–1124.
   PubMedGoogle Scholar
• Allsworth JE, Ratner JA, Peipert JF. Trichomoniasis and other sexually transmitted infections: results from the 2001-2004 national health and nutrition examination surveys. Sex Transm Dis. 2009;36(12):738–744.
   PubMed Web of Science ®Google Scholar
• Howe K, Kissinger PJ. Single-dose compared with multidose metronidazole for the treatment of trichomoniasis in women: a meta-analysis. Sex Transm Dis. 2017;44(1):29–34.
   PubMedGoogle Scholar
• Kissinger P, Muzny CA, Mena LA, et al., Single-dose versus 7-day-dose metronidazole for the treatment of trichomoniasis in women: an open-label, randomised controlled trial. Lancet Infect Dis. 18(11): 1251–1259. 2018.
   PubMed Web of Science ®Google Scholar
• Muzny CA, Richter S, Kissinger P. Is it time to stop using single-dose oral metronidazole for the treatment of trichomoniasis in women? Sex Transm Dis. 2019;46(5):e57–e59.
   PubMedGoogle Scholar
• Robinson SC. Trichomonal vaginitis resistant to metranidazole. Can Med Assoc J. 1962;86(14):665.
   PubMed Web of Science ®Google Scholar
• Graves KJ, Novak J, Secor WE, et al. A systematic review of the literature on mechanisms of 5-nitroimidazole resistance in Trichomonas vaginalis. Parasitology. 2020;147(13):1383–1391.
   PubMedGoogle Scholar
• Kirkcaldy RD, Augostini P, Asbel LE, et al. Trichomonas vaginalis antimicrobial drug resistance in 6 US cities, STD surveillance network, 2009-2010. Emerg Infect Dis. 2012;18(6):939–943.
   PubMed Web of Science ®Google Scholar
• Lossick JG, Muller M, Gorrell TE. In vitro drug susceptibility and doses of metronidazole required for cure in cases of refractory vaginal trichomoniasis. J Infect Dis. 1986;153(5):948–955.
   PubMed Web of Science ®Google Scholar
• Faught BM, Harris K. The history of secnidazole. [cited May 16, 2022]. Available from: https://www.npwomenshealthcare.com/history-of-secnidazole/
   Google Scholar
• Hillier SL, Nyirjesy P, Waldbaum AS, et al. Secnidazole treatment of bacterial vaginosis: a randomized controlled trial. Obstet Gynecol. 2017;130(2):379–386.
   PubMed Web of Science ®Google Scholar
• Schwebke JR, Morgan FG Jr., Koltun W, et al. A phase-3, double-blind, placebo-controlled study of the effectiveness and safety of single oral doses of secnidazole 2 g for the treatment of women with bacterial vaginosis. Am J Obstet Gynecol. 2017;217(6):678 e1–678 e9.
   Google Scholar
• Benazet F, Guillaume L. Amoebecide and trichomonacide activities of secnidazole in the laboratory. Bull Soc Pathol Exot Filiales. 1976;69(4):309–319.
   PubMedGoogle Scholar
• Ghosh AP, Aycock C, Schwebke JR. In vitro study of the susceptibility of clinical isolates of trichomonas vaginalis to metronidazole and secnidazole. Antimicrob Agents Chemother. 2018;62(4):e02329–17.
   PubMedGoogle Scholar
• Muzny CA, Schwebke JR, Nyirjesy P, et al., Efficacy and safety of single oral dosing of secnidazole for trichomoniasis in women: results of a phase 3, randomized, double-blind, placebo-controlled, delayed-treatment study. Clin Infect Dis. 73(6): e1282–e1289. 2021.
   PubMedGoogle Scholar
• Nyirjesy P, Schwebke JR. Secnidazole: next-generation antimicrobial agent for bacterial vaginosis treatment. Future Microbiology. 2018;13(5):507–524.
   PubMedGoogle Scholar
• Gillis JC, Wiseman LR, Secnidazole. A review of its antimicrobial activity, pharmacokinetic properties and therapeutic use in the management of protozoal infections and bacterial vaginosis. Drugs. 1996;51(4):621–638.
   PubMed Web of Science ®Google Scholar
• Edwards DI. Nitroimidazole drugs–action and resistance mechanisms. I. mechanisms of action. J Antimicrob Chemother. 1993;31(1):9–20.
   PubMed Web of Science ®Google Scholar
• Muller M. Reductive activation of nitroimidazoles in anaerobic microorganisms. Biochem Pharmacol. 1986;35(1):37–41.
   PubMedGoogle Scholar
• Darpo B, Xue H, Adetoro N, et al. Thorough QT/QTc evaluation of the cardiac safety of secnidazole at therapeutic and supratherapeutic doses in healthy individuals. J Clin Pharmacol. 2018;58(3):286–293.
   PubMedGoogle Scholar
• Pentikis HS, Adetoro N. Two phase 1, open-label, single-dose, randomized, crossover studies to assess the pharmacokinetics, safety, and tolerability of orally administered granules of secnidazole (2 g) in healthy female volunteers under different administration conditions. Clin Pharmacol Drug Dev. 2018;7(5):543–553.
   PubMedGoogle Scholar
• Videau D, Niel G, Siboulet A, et al., Secnidazole. A 5-nitroimidazole derivative with a long half-life. Br J Vener Dis. 54(2): 77–80. 1978.
   PubMedGoogle Scholar
• Populaire P, Decouvelaere B, Renard A, et al. Study of serum concentrations and urinary excretion of secnidazole after oral administration in man. Comparison with tinidazole. Pathol Biol. 1980;28(9):621–624.
   PubMedGoogle Scholar
• Ashiq B, Usman M, Ashraf M, et al. Comparative pharmacokinetics of metronidazole in healthy volunteers and in patients suffering from amoebiasis. Pak J Pharm. 2011;24. 41–46.
   Google Scholar
• Pentikis HS, Adetoro N, Braun CJ. Lack of a pharmacokinetic interaction between sym-1219 granules containing 2 grams of secnidazole and a combined oral contraceptive in a phase 1, randomized, open-label study in healthy female volunteers. Adv Ther. 2017;33(12):2229–2241.
   PubMed Web of Science ®Google Scholar
• Özbilgin A, Özbel Y, Alkan MZ, et al. Trichomoniasis in non-gonococcic urethritis among male patients. J Egypt Soc Parasitol. 1994;24(3):621–625.
   PubMedGoogle Scholar
• Siboulet A, Catalan F, Videau D, et al. La trichomonase urogénitale. Essais d’un imidazole à demi-vie longue: le secnidazole. Médecine et Maladies Infectieuses. 1977;7(9):400–404.
   Google Scholar
• Dyudyun AD, Polyon NM, Gorbuntsov VV. Secnidazole in complex treatment of patients with urogential trichomoniasis. Dermatovenerol Cosmetol Sexopathol. 2016;1(4):287–292.
   Google Scholar
• Chavoustie S, Shaw J, Pandey B, et al. Single-dose secnidazole is effective and safe for the treatment of bacterial vaginosis in adolescent girls. 24th Nurse Practitioners in Women’s Health’s Annual Premier Women’s Healthcare VirtualConference; 2021 October 13-16; Virtual meeting.
   Google Scholar
• Chavoustie SE, Gersten JK, Samuel MJ, et al. A phase 3, multicenter, prospective, open-label study to evaluate the safety of a single dose of secnidazole 2 g for the treatment of women and postmenarchal adolescent girls with bacterial vaginosis. J Womens Health (Larchmt). 2018;27(4):492–497.
   PubMedGoogle Scholar
• Moraes ME, Cunha GH, Bezerra MM, et al. Efficacy of the mentha crispa in the treatment of women with trichomonas vaginalis infection. Arch Gynecol Obstet. 2012;286(1):125–130.
   PubMed Web of Science ®Google Scholar
• Kissinger P, Mena L, Levison J, et al., A randomized treatment trial: single versus 7-day dose of metronidazole for the treatment of Trichomonas vaginalis among HIV-infected women. J Acquir Immune Defic Syndr. 55(5): 565–571. 2010.
   PubMedGoogle Scholar
• Gatski M, Martin DH, Levison J, et al. The influence of bacterial vaginosis on the response to trichomonas vaginalis treatment among HIV-infected women. Sex Transm Infect. 2011;87(3):205–208.
   PubMedGoogle Scholar
• Aimakhu VE. Vaginal trichomoniasis: one stat dose of tinidazole compared with a seven-day course of metronidazole. West Afr Med J. 1975;23:97–100.
   Google Scholar
• Chaisilwattana P, Bhiraleus P, Patanaparnich P, et al. Double blind comparative study of tinidazole and ornidazole as a single dose treatment of vaginal trichomoniasis. J Med Assoc Thai. 1980;63(8):448–453.
   PubMedGoogle Scholar
• Chaudhuri P, Drogendijk AC. A double-blind controlled clinical trial of carnidazole and tinidazole in the treatment of vaginal trichomoniasis. Eur J Obstet Gynecol Reprod Biol. 1980;10(5):325–328.
   PubMedGoogle Scholar
• Gabriel G, Robertson E, Thin RN. Single dose treatment of trichomoniasis. J Int Med Res. 1982;10(2):129–130.
   PubMedGoogle Scholar
• Hillstrom L, Pettersson L, Palsson E, et al. Comparison of ornidazole and tinidazole in single-dose treatment of trichomoniasis in women. Br J Vener Dis. 1977;53(3):193–194.
   PubMedGoogle Scholar
• Lyng J, Christensen J. A double-blind study of the value of treatment with a single dose tinidazole of partners to females with trichomoniasis. Acta Obstet Gynecol Scand. 1981;60(2):199–201.
   PubMedGoogle Scholar
• Mati JK, Wallace RJ. The treatment of trichomonal vaginitis using a single dose of tinidazole by mouth. East Afr Med J. 1974;51(12):883–888.
   PubMedGoogle Scholar
• Prasertsawat PO, Jetsawangsri T. Split-dose metronidazole or single-dose tinidazole for the treatment of vaginal trichomoniasis. Sex Transm Dis. 1992;19(5):295–297.
   PubMedGoogle Scholar
• Rees PH, McGlashan HE, Mwega V. Single-dose treatment of vaginal trichomoniasis with tinidazole. East Afr Med J. 1974;51(11 SPEC NO):782–785.
   PubMedGoogle Scholar
• U.S. Food and Drug Administration. Drug Approval Package: tindamax (Tinidazole) Tablets 2004. Accesssed on December 4, 2021 at https://www.accessdata.fda.gov/drugsatfda_docs/nda/ 2004/21-618_21-681_21-682_Tindamax.cfm
   Google Scholar
• Hobbs MM, Sena AC. Modern diagnosis of Trichomonas vaginalis infection. Sex Transm Infect. 2013;89(6):434–438.
   PubMedGoogle Scholar
• Beric B, Pribicevic V, Djordjevic M, et al. Clinical studies on the therapeutic effect of tinidazole (“Fasigyn”) during treatment of urogenital trichomonas infections in women and men (with comparative laboratory studies on the effect of metronidazole and tinidazole). Zentralbl Gynakol. 1978;100(24): 1594–1599
   PubMedGoogle Scholar
• Massa M, Arias B, Subiabre V, et al. Therapeutic trial of Trichomonas vaginalis in male by using a single dose of tinidazole (author’s transl). Bol Chil Parasitol. 1976;31(1–2):46–47.
   PubMedGoogle Scholar
• Wallin J, Forsgren A. Tinidazole–a new preparation for T. vaginalis infections. II. clinical evaluation of treatment with a single oral dose. Br J Vener Dis. 1974;50(2):148–150.
   PubMedGoogle Scholar
• Lupin Pharmaceuticals Inc. SOLOSEC® (secnidazole): full Prescribing Information. 2022.
   Google Scholar
• Pfizer Inc. FLAGYL® (metronidazole): full prescribing Information. 2021.
   Google Scholar
• Mission Pharmacal Inc. TINDAMAX® (tinidazole): full prescribing Information. 2019.
   Google Scholar
• ClinicalKey® [Internet]. Elsevier. 2022. [cited May 1, 2022]. Available from: https://www.elsevier.com/solutions/clinicalkey.
   Google Scholar
• Fjeld H, Raknes G. Is combining metronidazole and alcohol really hazardous? Tidsskr Nor Laegeforen. 2014;134(17):1661–1663.
   PubMedGoogle Scholar
• Pentikis H, Eder S, Kaufman G, et al. Secnidazole, an approved single dose drug for bacterial vaginosis, does not cause reproductive toxicity in animals. American Academy of Obstetricians and Gynecologists: Seattle WA. 2020 April 24-27.
   Google Scholar
• Burtin P, Taddio A, Ariburnu O, et al. Safety of metronidazole in pregnancy: a meta-analysis. Am J Obstet Gynecol. 1995;172(2 Pt 1):525–529.
   PubMed Web of Science ®Google Scholar
• Piper JM, Mitchel EF, Ray WA. Prenatal use of metronidazole and birth defects: no association. Obstet Gynecol. 1993;82(3):348–352.
   PubMed Web of Science ®Google Scholar
• Sheehy O, Santos F, Ferreira E, et al. The use of metronidazole during pregnancy: a review of evidence. Curr Drug Saf. 2015;10(2):170–179.
   PubMed Web of Science ®Google Scholar
• Czeizel AE, Kazy Z, Vargha P. Oral tinidazole treatment during pregnancy and teratogenesis. Int J Gynaecol Obstet. 2003;83(3):305–306.
   PubMedGoogle Scholar
• Subramanian C, Sobel JD. A case of high-level metronidazole-resistant trichomoniasis in pregnancy successfully treated. J Low Genit Tract Dis. 2011;15(3):248–249.
   PubMedGoogle Scholar
• Muzny CA, Kardas P. A narrative review of current challenges in the diagnosis and management of bacterial vaginosis. Sex Transm Dis. 2020;47(7):441–446.
   PubMedGoogle Scholar
• Kissinger P. Trichomonas vaginalis: a review of epidemiologic, clinical and treatment issues. BMC Infect Dis. 2015;15:307.
   PubMed Web of Science ®Google Scholar
• Bartley JB, Ferris DG, Allmond LM, et al. Personal digital assistants used to document compliance of bacterial vaginosis treatment. Sex Transm Dis. 2004;31(8):488–491.
   PubMed Web of Science ®Google Scholar
• Srinivasan S, et al. An antimicrobial bioassay to assess adherence to metronidazole treatment for bacterial vaginosis. Infectious Diseases Society of Gynecology Annual Meeting (Virtual).; 2021 July 29-30.
   Google Scholar